NEUROCOGNITIVE DISORDERS
Clinical trials for NEUROCOGNITIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new NEUROCOGNITIVE DISORDERS trials appear
Sign up with your email to follow new studies for NEUROCOGNITIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising Alzheimer's drug donanemab enters final phase trial
Disease control OngoingThis study tests whether donanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,500 participants with mild symptoms and brain amyloid plaques will receive the drug or a placebo for up to 93 weeks. The main goal is to see if donanemab help…
Matched conditions: NEUROCOGNITIVE DISORDERS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 26, 2026 04:06 UTC
-
New dosing strategy aims to make Alzheimer's drug safer
Disease control OngoingThis study tests whether changing the dose schedule of donanemab can lower the risk of a brain swelling side effect called ARIA-E while still clearing amyloid plaques. About 1,175 adults with early symptomatic Alzheimer's will receive different dosing regimens over 91 weeks. The …
Matched conditions: NEUROCOGNITIVE DISORDERS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Zapping the brain to spark motivation in seniors
Symptom relief OngoingThis study tests whether a gentle, non-invasive brain stimulation technique called tDCS, combined with computer-based cognitive training, can reduce apathy in older adults with mild memory or thinking problems. Apathy—a lack of motivation, interest, or initiative—is common in thi…
Matched conditions: NEUROCOGNITIVE DISORDERS
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated May 26, 2026 04:05 UTC